Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CDK1 | P06493 | 17/20 | 0.54 |
| ▸ | CCNB1 | P14635 | 1/20 | 0.54 |
| ▸ | CCNE1 | P24864 | 1/20 | 0.54 |
| ▸ | CDK2 | P24941 | 1/20 | 0.54 |
| ▸ | ADORA2A | P29274 | 2/20 | 0.48 |
| ▸ | ADORA1 | P30542 | 2/20 | 0.48 |
| ▸ | TMIGD3 | P0DMS9 | 1/20 | 0.48 |
| ▸ | ADORA2B | P29275 | 1/20 | 0.48 |
| ▸ | PRKCA | P17252 | 5/20 | 0.46 |
| ▸ | PI4KA | P42356 | 1/20 | 0.44 |
| ▸ | PI4K2B | Q8TCG2 | 1/20 | 0.44 |
| ▸ | PI4K2A | Q9BTU6 | 1/20 | 0.44 |
| ▸ | PI4KB | Q9UBF8 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12724436 | 0.83 | CDK1 (0.53) | CDK1CCNB1CCNE1CDK2ADORA2A | |
| SCHEMBL13708308 | 0.79 | CDK1 (0.49) | CDK1CCNB1CCNE1CDK2ADORA2A | |
| SCHEMBL29141662 | 0.78 | ADORA2A (0.63) | CDK1CCNB1CCNE1CDK2ADORA2A | |
| SCHEMBL12702590 | 0.75 | PI4KA (0.44) | CDK1CCNE1CDK2ADORA2AADORA1 | |
| SCHEMBL25231114 | 0.74 | STAT3 (0.49) | CDK1CCNB1CCNE1CDK2 | |
| SCHEMBL5839632 | 0.74 | CDK1 (0.71) | CDK1CCNB1CCNE1CDK2PRKCA | |
| SCHEMBL26036734 | 0.72 | CDK1 (0.67) | CDK1CCNB1CCNE1CDK2ADORA2A | |
| SCHEMBL8767031 | 0.70 | CCNE1 (1.00) | CDK1CCNB1CCNE1CDK2ADORA2A | |
| SCHEMBL5842067 | 0.69 | CDK1 (0.84) | CDK1ADORA2AADORA1TMIGD3ADORA2B | |
| SCHEMBL15354451 | 0.69 | CDK1 (0.73) | CDK1CCNB1CCNE1CDK2ADORA2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110092451-A1 | NUCLEOTIDE ANALOGUES WITH QUATERNARY CARBON STEREOGENIC CENTERS AND METHODS OF USE | INSTITUT DE RECHERCHES CLINIQUES DE MONTREAL (CA) | 2011-04-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110092451-A1 | NUCLEOTIDE ANALOGUES WITH QUATERNARY CARBON STEREOGENIC CENTERS AND METHODS OF USE | NUDT1, NT5C3B, NTPCR | CDK1 1040/4885CCNB1 1212/4885CCNE1 1585/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.